Recurrent Ovarian Carcinoma Recruiting Phase 1 Trials for Rucaparib (DB12332)

IndicationStatusPhase
DBCOND0030000 (Recurrent Ovarian Carcinoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03552471Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerTreatment